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Abstract
Background: In an effort to achieve better cancer therapies, we elucidated the combination cancer therapy of
STI571 (an inhibitor of Bcr-Abl and clinically used for chronic myelogenous leukemia) and TNF-related apoptosis-
inducing ligand (TRAIL, a developing antitumor agent) in leukemia, colon, and prostate cancer cells.
Methods: Colon cancer (HCT116, SW480), prostate cancer (PC3, LNCaP) and leukemia (K562) cells were treated
with STI571 and TRAIL. Cell viability was determined by MTT assay and sub-G1 appearance. Protein expression and
kinase phosphorylation were determined by Western blotting. c-Abl and p73 activities were inhibited by target-
specific small interfering (si)RNA. In vitro kinase assay of c-Abl was conducted using CRK as a substrate.
Results: We found that STI571 exerts opposite effects on the antitumor activity of TRAIL. It enhanced cytotoxicity
in TRAIL-treated K562 leukemia cells and reduced TRAIL-induced apoptosis in HCT116 and SW480 colon cancer
cells, while having no effect on PC3 and LNCaP cells. In colon and prostate cancer cells, TRAIL caused c-Abl
cleavage to the active form via a caspase pathway. Interestingly, JNK and p38 MAPK inhibitors effectively blocked
TRAIL-induced toxicity in the colon, but not in prostate cancer cells. Next, we found that STI571 could attenuate
TRAIL-induced c-Abl, JNK and p38 activation in HCT116 cells. In addition, siRNA targeting knockdown of c-Abl and
p73 also reduced TRAIL-induced cytotoxicity, rendering HCT116 cells less responsive to stress kinase activation, and
masking the cytoprotective effect of STI571.
Conclusions: All together we demonstrate a novel mediator role of p73 in activating the stress kinases p38 and
JNK in the classical apoptotic pathway of TRAIL. TRAIL via caspase-dependent action can sequentially activate c-Abl,
p73, and stress kinases, which contribute to apoptosis in colon cancer cells. Through the inhibition of c-Abl-
mediated apoptotic p73 signaling, STI571 reduces the antitumor activity of TRAIL in colon cancer cells. Our results
raise additional concerns when developing combination cancer therapy with TRAIL and STI571 in the future.
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Background
The tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a tumor-selective, apoptosis-inducing
cytokine. By binding to the death receptors DR4 and
DR5, TRAIL can recruit the intracellular adaptor mole-
cule, Fas-associated protein with death domain (FADD),
to death domains present in the cytoplasmic region of
these receptors and form a death-inducing signaling
complex. FADD in turn can recruit and activate proxi-
mal caspase 8, which subsequently activates effector cas-
pase 3, either by direct processing via a protease cascade
or indirectly via a mitochondrial apoptotic pathway
[1,2]. Apart from the caspase activation cascade, TRAIL
can also activate c-Jun NH2-terminal kinase (JNK) and
p38, which are thought to be important for the induc-
tion of cell apoptosis [3-5].
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represents a breakthrough in the clinical application for
several human malignancies [6]. c-Abl is a ubiquitously
expressed non-receptor tyrosine kinase containing a
myristoylation site, SH2 and SH3 domains, a kinase
domain, DNA- and actin-binding domains, and nuclear
targeting and export signals [7]. Several reports showed
that c-Abl can be stimulated by physiological and phar-
macological stresses, such as UV, genotoxic agents,
growth factors, and TNF-a [8-10]. c-Abl is distributed
in both the cytoplasm and nucleus, where it plays dis-
tinct roles [11]. Nuclear c-Abl activation in response to
DNA damage, TNF-a, or FasL leads to cell growth
arrest and/or apoptosis [9,12,13]. In contrast, cytoplas-
mic c-Abl activated by growth factors or by extracellular
matrix proteins is involved in cytoskeletal remodeling
and cell growth [14,15]. Even though the mechanism by
which c-Abl drives cell death is not completely under-
stood, it might involve a combination of signals. In fact,
c-Abl regulates downstream molecules which are asso-
ciated with cell death/survival, including p73, p63, p53,
PKCδ,r e t i n o b l a s t o m a( R B ) ,c - J u n ,I Ba and mitogen-
activated protein kinases (MAPKs) [8-10,13,16]. The
direct transactivation of PUMA and Bax, and the
expression of death receptors by p73 were demonstrated
to contribute to c-Abl-mediated apoptosis [17,18].
STI571 (imatinib, Gleevec
®) is a specific inhibitor of
tyrosine kinases, such as Bcr-Abl, c-Abl, platelet-derived
growth factor receptor, and c-Kit [19]. It was approved
for the treatment of Philadelphia chromosome-positive
chronic myelogenous leukemia (CML) and gastrointest-
inal stromal tumors with constitutively active Bcr-Abl
and c-Kit [20-22]. As a front-line therapy, STI571 is tre-
mendously successful; however, STI571-resistant clones
that allow the disease to progress are appearing and
increasing. Thus the management of patients who are
resistant to STI571 with many conventional chemother-
apeutic agents still needs to be resolved. Moreover,
recent studies showing that c-Abl is highly active in
many aggressive breast cancer cell lines and involved in
cancer cell metastasis, proliferation, and survival have
raised strong interest in investigating STI571’s effects in
other solid tumors [15].
In an effort to achieve better cancer therapy, the pos-
sibility of combining TRAIL and STI571 in various can-
cer types is worth investigating. In fact, studies showed
that when co-treating STI571 with TRAIL, K562 (a Bcr-
Abl-positive human leukemia cell line) and melanoma
cells are more sensitive to death [23,24]. Moreover,
reports indicate that TRAIL can induce cell death in
CML cells that are refractory to STI571, and vice versa
STI571 can overcome TRAIL resistance in K562 cells
[25-27]. In this report we extend to study this combina-
tion in colon and prostate cancer cells. Both STI571 and
TRAIL alone have been reported to exert antitumor
activity in colon cancer cells [28,29]. Intriguingly, in this
study we found that STI571 can attenuate TRAIL-
induced cytotoxicity in colon cancer cells, whereas it
cannot affect TRAIL’s effect in prostate cancer cells. We
presented evidence that c-Abl mediation of TRAIL-
induced JNK and p38 activation is involved in the death
of colon cancer cells, but not of prostate cancer cells.
Moreover, p73 is the downstream effector of c-Abl
which propagates signals to JNK and p38.
Methods
Reagents
TRAIL was purchased from PeproTech (London, UK).
STI571 was kindly provided by Norvartis Pharma AG
(Basel, Switzerland). Rabbit monoclonal antibodies spe-
cific for caspase 3 and 8, phosphorylated p38, JNK, ERK,
and c-Abl were obtained from Cell Signaling Technol-
ogy (Beverly, MA, USA). Mouse antibodies for c-Abl,
JNK1, p38, and b-actin were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). The p73 antibody was
purchased from BD Pharmingen Technical (San Jose,
CA, USA). SB203580, SP600125, and z-Val-Ala-Asp-
fluromethylketone (zVAD) were purchased from Calbio-
chem (San Diego, CA, USA). GST-CRK (120-225) pro-
tein was obtained from Merck Millipore (Darmstadt,
Germany). All other chemicals were obtained from
Sigma Aldrich (St. Louis, MO, USA).
Cell culture
Human colon cancer HCT116 and SW480 cells, CML
K562 cells, and prostate cancer PC3 and LNCaP cells
obtained from American Type Culture Collection (Man-
assas, VA, USA) were grown in DMEM. All media were
supplemented with 10% (v/v) heat inactivated FBS, 100
U/ml penicillin and 100 μg/ml streptomycin. Cells were
incubated at 37°C in a humidified atmosphere of 5%
CO2 in air and were routinely sub-cultured every 2-3
days.
Measurement of cell viability
Cell viability was determined by 3-(4,5-dimethylthiazol-
2-yl) 2,5-diphenyltetrazolium bromide (MTT) at 1 mg/
ml for 30 min, then cells were dissolved in 100%
DMSO. The net absorbance (OD550 nm-OD630 nm)
was determined and indicated the enzymatic activity of
mitochondria and cell viability.
Apoptotic assay
After drug treatment, cells were harvested and washed
twice with PBS and fixed in iced 70% ethanol, then
stored at -20°C overnight. DNA extraction buffer (0.2 M
Na2HPO4 and 0.1 M citric acid; pH 7.8) was added at
room temperature for 30 min. Cells were then incubated
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pidium iodide (PI) for 30 min in the dark at room tem-
perature. Using a FACScan flow cytometer (BD
Biosciences), 10
4 cells were counted, and a lower DNA
content than that of the G0/G1 phase indicated apopto-
tic cells.
Western blotting
Cells were lysed by the addition of cold RIPA buffer
[150 mM NaCl, 50 mM Tris HCL, 0.1% SDS, 1% Triton
X-100, 1 mM PMSF, 2 mM NaF, Na3VO4, b-glycero-
phosphate and 2 mM EDTA, and fresh protease inhibi-
tor cocktail (Catalog no. P8340, purchased by Sigma
Aldrich)], and cell lysate was centrifuged at 14,000 × g
at 4°C for 20 min. The supernatant was harvested and
analyzed for protein content using protein assay dye.
Protein was denatured in sample buffer, then separated
on SDS-PAGE, and transferred to polyvinylidene
difluoride membranes using a semidry trans-blot system.
The blots were blocked for 1 h at room temperature
with Tris-Buffered saline (TBS, 50 mM Tris-HCl, pH
7.5, 150 mM NaCl) containing 5% non-fat milk. The
blots were washed three times with TBST (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, and 0.02% Tween 20) and
incubated with the indicated antibody at 4°C overnight.
Next day, the blots were incubated for 1 h at room tem-
perature with secondary antibody (1:5000 dilutions), and
detected by ECL detection reagent. To ensure that equal
amounts of sample protein were applied for electrophor-
esis, b-actin was used as an internal control.
Gene silencing
The siRNA duplexes specific for human c-Abl (cat. no.
L-003100-00) or p73 (cat. no. L-003331-00) were
obtained from Dharmacon RNA Technologies. The
siRNA for each group contained four RNA sequences in
a Smart Pool selected from the NCBI RefSeq Database
by a proprietary algorithm. The control non-targeting
pool is a pool of four functional non-targeting siRNAs
with guanine cytosine contents comparable to that of
the functional siRNA but lacking specificity for known
gene targets. To achieve gene silencing, we transfected
cells with the indicated siRNA for 24 h followed by
drug treatment; then the gene silencing effects were
evaluated by Western blot analysis.
Immunoprecipitation
For immunoprecipitation experiments, cells were
washed with ice-cold PBS once and then lysed in 1 ml
RIPA lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM
N a C l ,1 %T r i t o nX - 1 0 0 ,0 . 1 %S D S ,2m ME D T A ,2m M
NaF, 2 mM b-glycerolphosphate, 2 mM Na3VO4,1m M
PMSF, and protease inhibitor cocktails) and centrifuged
at 10,000 rpm, 4°C for 5 min. The supernatant was
collected and was pre-cleaned with 0.5 μgn o r m a lI g G
and 10 μl protein A-agarose beads at 4°C for 30 min for
each sample. After centrifugation, supernatant was incu-
bated with specific antibody at 4°C overnight, and then
10 μl protein A-agarose beads were added and rocked
for another 1 h. The immunocomplexes were washed
two times with cold RIPA buffer containing 150 mM
NaCl, two times with RIPA buffer containing 300 mM
NaCl and finally RIPA buffer containing 150 mM NaCl
again. SDS gel-loading buffer was added to the precipi-
tated complexes and heat the samples at 95°C for 5 min.
After spinning down the samples and loading the super-
natants onto the SDS-PAGE, immunoblotting analysis
was performed as described above.
In vitro c-Abl kinase assay
To evaluate kinase activity of c-Abl, HCT116 cells were
lysed in Tris-buffered saline-0.1% Triton X-100, and cell
lysates were pre-cleaned at 4°C for 30 min and then
immunoprecipitated with 1 μg anti-c-Abl (K-12) anti-
body at 4°C, 4 h. Afterwards 10 μl protein A-agarose
beads were added and rocked at 4°C for another 1 h.
The immunocomplexes were washed 5 times with cold
lysis buffer, and then twice with the kinase reaction buf-
fer (20 mM HEPES, pH 7.5 and 10 mM MgCl2). The
beads were then incubated at 30°C in 40 μl kinase reac-
tion buffer supplemented with 10 μCi of [g-
32P] ATP, 2
mM Na3VO4, 1 mM DTT, 10 μM ATP, protease inhibi-
tor cocktails and 1 μg GST-CRK (120-225). The reaction
was stopped by the addition of 10 μl 5× SDS-gel loading
buffer and boiling for 5 min. Reaction products were
run on 10% SDS-PAGE, followed by autoradiography.
Statistical evaluation
Data were expressed as the mean ± S.E.M. of at least
three experiments. Analysis of variance (ANOVA) was
used to assess the statistical significance of the differ-
ences, with a p value of < 0.05 considered statistically
significant.
Results
STI571 reduces TRAIL-induced cell apoptosis in colon
cancer but not in prostate cancer cells
A previous study revealed the beneficial cytotoxic
effects of STI571 and TRAIL against K562 cells, the
prototype cell model of CML [23]. Before being able to
understand the combined cytotoxic effects in other
cancer cell types, we first verified this action in K562
cells. Results shown in Figure 1A revealed that K562
cells were sensitive to STI571 at 1 ~ 10 μM, while
they were resistant to TRAIL at concentrations up to
100 ng/ml as previously reported [27]. Co-treatment
with STI571 and TRAIL led to increased cell death in
concentration- and time-dependent manners. In
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μM) alone induced a moderate loss of cell viability,
and TRAIL induced a more prominent toxicity at 50
ng/ml. The average of cell viability under 0.3 μM
STI571 and 50 ng/ml TRAIL treatment for 24 h
achieved 88 ± 5% (n = 15) and 52 ± 7% (n = 20) of
control, respectively. When pretreating cells with
STI571 (0.1 ~ 1 μM) for 30 min, followed by TRAIL
( 5 0n g / m l )f o r2 4h ,w ef o u n dt h a tt h e i rr e s p e c t i v e
responses in decreasing cell viability were not additive
(Figure 1B, left panel). Intriguingly, STI571 attenuated
TRAIL-induced cell death in a concentration-depen-
dent manner within 0.1 ~ 1 μM, but not at 10 μM. On
average, STI571 (0.3 μM) reduced TRAIL (50 ng/ml)-
induced cytotoxicity by approximately 20 ~ 25%, i.e.
increasing cell viability from 52 ± 7% to 72 ± 6%. This
cytoprotective effect of STI571 was also time depen-
dent (Figure 1B, right panel). STI571 also exerted a
Figure 1 Distinct effects of STI571 on TRAIL-induced cytotoxicity in cancer cells. K562 cells (A), colon cancer HCT116 cells (B), and SW480
cells (C) were pretreated with STI571 for 30 min, followed by TRAIL for 24 h, and then the cell viability was assessed by an MTT assay. Cell
viability was determined in some cases of K562 (A, right panel) and HCT116 cells (B, right panel) after drug treatment for different periods. In (D),
various cancer cells were treated with STI571 (1 μM) and TRAIL (50 ng/ml) for 24 h, and then the cell viability was determined. * p < 0.05,
indicating significant attenuation of TRAIL-induced cytotoxicity by STI571
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TRAIL-induced cytotoxicity (Figure 1C). Intriguingly,
unlike the protection seen in colon cancer cells, we
found that TRAIL-induced cell death in prostate can-
cer PC3 and LNCaP cells were barely reversed by
STI571, which alone had no significant effect on cell
viability in both cell types (Figure 1D).
We used pharmacological and biochemical approaches
to verify whether the reduction of TRAIL-induced cell
death by STI571 involves a caspase-dependent apoptotic
pathway. We found that zVAD (a pan-caspase inhibitor)
completely reversed TRAIL-induced cell death, but had
no effect on STI571 (Figure 2A). Moreover, with a simi-
lar effect on the MTT assay, STI571 reduced TRAIL-
induced sub-G1 fractions (Figure 2B). We also analyzed
the proteolytic processing of procaspase 3 (an effector
caspase), and found that TRAIL treatment alone
resulted in the processing of procaspase 3 (Figure 2C).
However, when pretreated with STI571, the proteolysis
of procaspase 3 was reduced.
TRAIL activates c-Abl in colon and prostate cancer cells
To determine if TRAIL can activate c-Abl, we deter-
mined levels of c-Abl phosphorylation at Tyr412, which
can stimulate kinase to full catalytic activity [30]. More-
over, we also determined if c-Abl could be cleaved by
TRAIL-induced caspase activation. Previous studies
showed that caspase-mediated cleavage of c-Abl pro-
duced kinase fragments for increased activity [31-33]. As
shown in Figure 3A, TRAIL time-dependently induced
c-Abl cleavage accompanied by caspase 8 activation in
HCT116 cells. Neither action of TRAIL was affected by
the presence of STI571. Similarly, TRAIL-elicited c-Abl
cleavage in LNCaP and PC3 cells was not changed by
STI571 (Figure 3B). Next, we tested if TRAIL could
induce c-Abl activation, and if this effect was dependent
on caspase. As shown in Figure 3C, c-Abl phosphoryla-
tion at Tyr412 in HCT116 cells was increased following
TRAIL treatment, and this effect was inhibited by
STI571 and zVAD. On the other hand, TRAIL-induced
c-Abl cleavage was not changed by STI571, but was
inhibited by zVAD. To determine the effects of TRAIL
and STI571 on c-Abl activity, in vitro kinase activity
assay using GST-CRK (120-225) as a substrate was per-
formed. As reported, CRK adaptor protein is a kinase
substrate of c-Abl, and its phosphorylation at Tyr 221
by c-Abl functions as a negative regulator of cell moti-
lity and cell survival [34,35]. We found that c-Abl activ-
ity was increased following TRAIL treatment for 3 h,
and this effect was inhibited in the presence of STI571
(Figure 3D). These results suggest that the enzymatic
activation of caspase is required for c-Abl cleavage and
activation.
Protection of HCT116 cells against TRAIL by STI571 is
associated with JNK and p38 signaling
S i n c eJ N Ka n dp 3 8M A P Ka r ei m p o r t a n ti ni n d u c i n g
apoptosis, we investigated their involvement in TRAIL-
induced cell death, and their linkage to the action of
STI571. As a result, TRAIL alone significantly induced
JNK and p38 phosphorylation, but did not affect ERK
activation. Pretreatment with STI571 resulted in reduc-
tions in JNK and p38 activation (Figure 4A, left panel).
Moreover, we found that SP600125 (JNK inhibitor) and
SB203580 (p38 inhibitor) could partially reverse TRAIL-
induced cell death, but did not produce further
increased protection in combination with STI571 (Fig-
ure 4A, right panel). Nevertheless, in LNCaP and PC3
cells, neither SB203580 nor SP600125 treatment, either
alone or in combination, altered TRAIL-induced cyto-
toxicity (Figure 4B, C, right panel). And unlike the
effects in HCT116 cells, STI571 cannot alter TRAIL-
induced p38 and JNK activation (Figure 4B, C, left
panel). These results suggest the involvement of JNK
and p38 in TRAIL-induced cell death in colon cancer
cells, and the protective mechanism of STI571 might be
related to both kinases.
Following observing the ability of STI571 to inhibit
TRAIL-activated stress kinases in HCT116 cells, we
were wondering the stimuli-specific action of STI571.
Thus we tested effects of STI571 on stress kinase activa-
tion caused by anisomycin, which is known to be a
potent inducer of JNK and p38 [36]. Results revealed
that anisomycin rapidly activated JNK and p38 phos-
phorylation in HCT116 cells, and the extents of activa-
tion were not affected by STI571 (Figure 4D, left panel).
Moreover, anisomycin alone induced cell death, but this
effect was not reversed by pretreatment with STI571,
SB203580, or SP600125 (Figure 4D, right panel). These
results suggest that STI571-elicited attenuation of stress
kinase activation is not a general action, but is specific
in colon cancer cells in response to the extrinsic death
inducer, TRAIL.
Reduced cell susceptibility to TRAIL by STI571 is
dependent on c-Abl and p73
To understand the role of c-Abl in STI571’sa c t i o n ,w e
used RNA-silencing technology. Results showed that
TRAIL-induced cytotoxicity was reversed by c-Abl
siRNA (Figure 5A), and under this condition, STI571-
induced protection was no longer observed. Moreover,
c-Abl siRNA reduced p38 and JNK activations after
TRAIL treatment compared to cells transfected with
scrambled control siRNA (Figure 5B). These data sug-
gest that c-Abl is required for HCT116 cells to be
responsive to TRAIL-induced p38 and JNK signaling,
and both in turn contribute to cell death.
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Page 5 of 14Figure 2 TRAIL-induced apoptosis in HCT116 cells is attenuated by STI571. (A) Cells were pretreated with zVAD (20 μM) for 30 min,
followed by the addition of STI571 or TRAIL. After 24 h, cell viability was determined by the MTT assay. (B) After treatment with STI571 and/or
TRAIL for 6 or 9 h, cells were labeled with PI, and the cell population with sub-G1 expression was determined by flow cytometry. (C) After
treatment with STI571 (0.3 μM) and/or TRAIL (50 ng/ml) for 1 ~ 4 h, cell lysates were harvested for immunoblotting of caspase 3. * p < 0.05,
indicating significant reduction of TRAIL-induced apoptosis by zVAD (A) and STI571 (B). Traces in (C) were representative of at least three
separate experiments with similar results.
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of c-Abl, plays a role in regulating cell death [37]. To
understand the roles played by p73 in TRAIL-induced
cell death and STI571-induced TRAIL resistance, we
transfected p73 siRNA in HCT116 cells. Results showed
that under p73 knockdown condition, TRAIL-induced
cell death (Figure 6A), caspase 3 cleavage (Figure 6B),
JNK and p38 activation (Figure 6C) were inhibited as
seen with STI571. Meanwhile with p73 silencing, the
inhibitory effects of STI571 on cell death, and activation
of MAPKs and caspase 3 were not further observed.
The fact that p73 targeted by siRNA induced similar
inhibitory effects as did STI571 on TRAIL responses
suggests that p73 is crucial for TRAIL-elicited cell death
and mediates the actions of STI571.
Discussion
TRAIL is a potential anticancer agent, and drug combi-
nation therapy to improve its effectiveness has recently
garnered much attention. In this respect, its advantaged
combination with STI571 has been shown in CML and
melanoma. TRAIL and STI571 can mutually overcome
respective death resistance in CML [23,25,27]. Co-treat-
ment with STI571 also enhances the susceptibility of
melanoma cells to TRAIL [24]. Based on previous pro-
mising results of this combination effect, we were
Figure 3 TRAIL induces c-Abl activation and cleavage in colon and prostate cancer cells.H C T 1 1 6( A ) ,L N C a P ,a n dP C 3( B )c e l l sw e r e
treated with TRAIL (50 ng/ml) and/or STI571 (0.3 μM) for different time periods; then protein levels of c-Abl, caspase 8, and b-actin were
determined. In (C), HCT116 cells were treated with STI571 (S, 0.3 μM), zVAD (Z, 20 μM), and/or TRAIL (T, 50 ng/ml) for 4 h. Then protein levels of
both the total and Tyr412 phosphorylated forms of c-Abl were determined. Traces were representative of three separate experiments with similar
results. The extent of Tyr412 phosphorylation as an index of kinase activation was quantified by standardizing the total non-cleaved c-Abl level
and presented in parentheses. (D) After treating HCT116 cells with STI571 (S, 0.3 μM) and/or TRAIL (T, 50 ng/ml) for 3 h, c-Abl kinase activity was
determined by in vitro kinase assay using GST-CRK as substrate.
Huang et al. Journal of Biomedical Science 2012, 19:35
http://www.jbiomedsci.com/content/19/1/35
Page 7 of 14Figure 4 Protection of HCT116 cells against TRAIL by STI571 is associated with JNK and p38 signaling. HCT116 (A, D), LNCaP (B), and
PC3 cells (C) were treated with TRAIL (50 ng/ml), STI571 (0.3 μM) and/or anisomycin (10 μM) for the time indicated. Then protein levels of JNK,
p38, and ERK were determined (left panel). Traces were representative of three separate experiments with similar results. In some experiments,
cells were pretreated with SB203580 (10 μM), SP600125 (20 μM), STI571 (0.3 μM) and/or zVAD (20 μM) as indicated for 30 min, and then TRAIL
(50 ng/ml) or anisomycin (10 μM) was added. After 24 h incubation, cell viability was determined by the MTT assay (right panel). * p < 0.05,
indicating a significant reduction in cell apoptosis by STI571.
# p < 0.05, indicating a significant reduction in TRAIL-elicited apoptosis by kinase
inhibitors.
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confer higher susceptibility towards co-treatment of
b o t ha n t i t u m o ra g e n t s .T ot h i se n d ,i nt h i ss t u d yw e
chose colon cancer and prostate cancer cells, where
STI571 and TRAIL alone have been demonstrated to
exert antitumor activity [28,29,38,39].
Here we found that the action of TRAIL in colon can-
cer cells is sensitive to zVAD, confirming the process of
Figure 5 STI571-induced reduction of cell susceptibility to TRAIL is dependent on c-Abl. (A) HCT116 cells were transfected with c-Abl
siRNA, and 24 h after transfection the intracellular c-Abl protein level was determined. In some experiments, cells were treated with TRAIL (50
ng/ml) and/or STI571 (0.3 μM) as indicated for another 24 h, and cell viability was determined. * p < 0.05, indicating a significant reduction in
apoptosis by STI571.
# p < 0.05, indicating a significant reduction of TRAIL-elicited apoptosis by c-Abl siRNA. (B) In some experiments under c-Abl
siRNA treatment, JNK and p38 activation by TRAIL were determined. Data of immunoblotting were representative of three separate experiments
with similar results.
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STI571 (of around 12% at 0.3 μM) was not affected by
zVAD, ruling out the process of apoptosis. Instead, a
cell proliferation analysis indicated that STI571 can inhi-
bit HCT116 cell growth (data not shown) as reported in
HT29 colon cancer cells [40]. When treating HCT116
cells with STI571 and TRAIL, an antagonistic result was
obtained, suggesting that STI571 can regulate the death
effect of TRAIL. Such antagonistic effect of STI571
exhibited the concentration-dependency at 0.1 ~ 1 μM.
However, a higher concentration of STI571 (10 μM) did
not display this effect. Currently we cannot explain the
latter observation for the interaction of STI571 and
TRAIL, but it is suggested that multiple mechanisms
participate in regulating TRAIL’s effect by STI571.
Many cytotoxic chemotherapeutic drugs sensitize can-
cer cells to TRAIL by increasing its receptor expression
[29]. In this respect, STI571 did not change caspase 8
activation caused by TRAIL, ruling out STI571’sa c t i o n
is related to death receptor expression or activation of
upstream death signals. Moreover, we conducted immu-
noblotting with DR4 and DR5 antibodies and flow cyto-
metry to detect surface DR5 expression. The lack of any
effects in these experiments (data not shown) indicates
that STI571 does not change expression of the death
receptors.
Figure 6 STI571-induced cell resistance to TRAIL is dependent on p73. (A) HCT116 cells were transfected with p73 siRNA, and were treated
with TRAIL (50 ng/ml) and/or STI571 (0.3 μM) as indicated. Cell viability at 24 h and protein expression of p73 were determined. * p < 0.05,
indicating a significant reduction of TRAIL-induced apoptosis by STI571.
# p < 0.05, indicating a significant difference of TRAIL-elicited cell death
between p73 siRNA and scrambled control cells. In some experiments, caspase 3 (B), JNK and p38 activations (C) were measured by assessing
their cleavage form and phosphorylation state. Data of immunoblotting were representative of three separate experiments with similar results.
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p38 and JNK followed by caspase 3 activation in HeLa
and HCT116 cells [4,29]. Thus, sensitizing cancer cells
to TRAIL through activating JNK and p38, which subse-
quently regulate pro-apoptotic and anti-apoptotic Bcl-2
family members and p53, becomes a promising
approach to cancer therapy [41-44]. Using pharmacolo-
gical inhibitors, we showed the involvement of JNK and
p38 in TRAIL-induced cytotoxicity and in STI571-
induced cell protection in HCT116 cells. Under condi-
tions of p38 or JNK inhibition, TRAIL-elicited cell death
was inhibited. Moreover, STI571 also inhibited activa-
tion of both stress kinases induced by TRAIL, but no
longer exerted its cytoprotection when TRAIL-elicited
MAPK activation was already abolished. We thus sug-
gest that inhibition of JNK and p38 are involved in
STI571-induced protection.
Activation of c-Abl by certain DNA-damaging agents
contributes to cell apoptosis via p53-dependent and
-independent mechanisms. First of all, Yuan and collea-
gues found that c-Abl is activated by infrared and in
turn leads to G1 growth arrest via a p53-dependent
mechanism. However, they als on o t e dt h a tt r a n s f e c t i n g
p53-/- cells with wild-type c-Abl could still sensitize cell
apoptosis in response to DNA damage, whereas expres-
s i n gt h ek i n a s ed e a dc - A b lc o u l dn o t[ 1 0 ] .L a t e r ,t h e y
identified p73, a homologue of p53, as a downstream
mediator of c-Abl for inducing cell apoptosis [37,45]. c-
Abl was shown to stabilize p73 through phosphoryla-
tion-dependent posttranslational regulation
[17,18,45-47]. To determine if c-Abl and p73 are targets
of STI571 in initiating cytoprotection, we silenced c-Abl
and p73 using the siRNA approach. As the results seen
in experiments using the kinase inhibitor, we found that
downregulation of c-Abl or p73 rendered cells less sen-
sitive to TRAIL for JNK and p38 activation as well as
for cell apoptosis. We therefore conclude that c-Abl-
dependent p73 activation is involved in TRAIL-induced
apoptosis in HCT116 cells. Moreover, in agreement
with previous findings [29,48], we did not observe
effects of TRAIL to increase protein expression of p53
and Bax in p53-proficient HCT116 cells (data not
shown).
The major function identified for p73 is induction of
apoptosis [19,20,49,50]. Studies demonstrated the cross-
talk between p73 and stress kinases (JNK and p38),
leading to the upregulation of apoptotic Bcl-2 proteins
and cell death. JNK can form a complex with p73 and
phosphorylate p73 at multiple residues [51]. Activation
of c-Abl by DNA damage was also reported to activate
p38, and p38 is then sufficient to induce p73 phosphor-
ylation and enhance its transcriptional activity
[49,52,53]. Thus, activation of p73 by c-Abl may play an
important role in cancer therapy, especially in cancer
cells that lose p53 function, but express p73. In this
study, our results indicate that a c-Abl-dependent p73
pathway is involved in JNK and p38 activation, and
mediates the death mechanism of TRAIL in colon can-
cer cells. In this respect, activated p73 via caspase path-
way has been shown to localize to mitochondria and
augment cytochrome c release and cell death [50].
Therefore, in addition to being a transcription factor,
p73 is speculated to have novel protein-protein interact-
ing roles which contribute to enhancement of cell apop-
tosis. Although JNK can directly interact with p73 [51],
it still needs to identify the interactive proteins linking
p73 to p38. Apart from the involvement of c-Abl-p73 in
stress kinase activation caus e db yT R A I L ,w es t i l lc a n -
not rule out other signaling pathways that link death
receptors to JNK and p38. In this respect, TRAIL might
also activate JNK through the adaptor molecules, TNF
receptor-associated death domain (TRADD), FADD,
TNF receptor-associated factor 2 (TRAF2) and recep-
tor-interacting protein (RIP) [54-56]. Moreover, mito-
gen-activated protein kinase kinase 1 (MEKK1) and
MEKK4 activated by caspase 8 were demonstrated to be
responsible for TRAIL-induced JNK or p38 activation
[57].
In this study, we also demonstrated caspase-dependent
c-Abl cleavage and activation in TRAIL-treated colon
and prostate cancer cell lines. Many studies demon-
strated that the phosphorylation of c-Abl at Tyr412 by
receiving signals through Src kinases, receptor tyrosine
kinases or autophosphorylation, is an index for full c-
Abl activation [30]. Moreover, besides phosphorylation-
mediated activation, c-Abl can be cleaved by caspase in
the C-terminal region [31-33]. Such cleavage occurs
mainly in the cytoplasmic compartment and generates a
120-kDa fragment that can lead to increased kinase
activity and/or accumulation in the nucleus [31,32]. Our
present results clearly demonstrate the occurrence of
both phosphorylation activation and proteolytic activa-
tion of c-Abl following TRAIL stimulation in HCT116
cells. Moreover, both activating mechanisms are
mediated by a caspase pathway, and the increase of
Tyr412 phosphorylation is occurred on residual non-
cleaved c-Abl. Notably STI571 did not alter the c-Abl
cleavage caused by TRAIL, but partially reduced the
extent of Tyr412 phosphorylation. These results suggest
the existence of c-Abl autophosphorylation at Tyr412 in
TRAIL-stimulated cells, and also imply a cleavage-inde-
pendent, but caspase-mediated mechanism for c-Abl
activation. In this respect, a previous report showed that
TNF-a can activate c-Abl and upregulate apoptotic p73
function via a caspase-dependent elimination of retino-
blastoma protein, and thus unleashing the nuclear apop-
totic effector, c-Abl [8]. Currently the molecular events
linking caspase to non-cleaved c-Abl activation
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further investigation is required.
In contrast to reduced TRAIL sensitivity in colon can-
cer cells, STI571 did not change the susceptibility of
PC3 and LNCaP cells to TRAIL. We ruled out such cell
type-specific effects of STI571 being related to c-Abl
protein expression. Similar expression levels of c-Abl
were observed in HCT116, SW480, PC3, and LNCaP
cells (data not shown). Instead, we suggest that the
antitumor activity of TRAIL in colon and prostate can-
cers might involve distinctive regulation and complex
apoptotic pathways. In prostate cancers, neither p38 nor
JNK activation by TRAIL is involved in cell death, while
STI571 can still slightly inhibit TRAIL-induced JNK
activation in prostate cancers. Moreover, TRAIL-
mediated c-Abl cleavage displayed the same pattern in
HCT116 and LNCaP cells. Therefore, these results
further support the notion that the cell type-specific
Figure 7 Signaling pathway for the cytoprotective effect of STI571 in TRAIL-treated colon cancer cells. In addition to induce classical
apoptotic cascade elicited by caspases, TRAIL-induced apoptosis in colon cancer cells requires p38 and JNK activation. We propose both kinase
activation by TRAIL relies on activation of c-Abl, and the downstream targeting molecule p73. Abrogating c-Abl activity by STI571 can reduce
TRAIL-mediated stress kinase activation and reduce cell apoptosis. Other signaling cascades and molecules involved in the TRAIL-induced stress
kinases activation, such as TRAF2, RIP1, and MEKK1/MEKK4, cannot be excluded.
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dependent on the roles of p38 and JNK in cell death per
se.
Conclusions
We demonstrate a novel mediator role of p73 in activat-
ing the stress kinases, p38 and JNK, in the apoptotic
pathway of TRAIL (Figure 7). This action is initiated by
caspase-dependent c-Abl activation, and is a key
mechanism contributing to death receptor-mediated cell
apoptosis in colon cancer, but not prostate cancer cells.
Through inhibition of the c-Abl-mediated apoptotic p73
signaling, STI571 reduces the antitumor activity of
TRAIL. In this sense, this study is not in favor of the
cocktail therapy of STI571 and TRAIL in human colon
cancers, and also highlights the cancer-specific effect of
stress kinases on the antitumor activities of TRAIL.
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